Head-to-head · WeighScore
OnlyRx vs Zealthy
The verdict
OnlyRx takes it — 60.9/100 to 46.7/100.
OnlyRx grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. OnlyRx is a cash-pay GLP-1 telehealth platform offering compounded semaglutide and tirzepatide in both injection and oral disintegrating tablet (ODT) forms — an uncommon needle-free option.
We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | OnlyRx | Zealthy |
|---|---|---|
| WeighScore | 60.9/100 | 46.7/100 |
| Grade | C | C |
| Scorecard rank | #311 | #496 |
| Semaglutide | $179/mo (starting dose, promotional rate, compounded) | $286/mo (starting dose, plus a separate fee, compounded) |
| Tirzepatide | $249/mo (starting dose, compounded) | $351/mo (starting dose, plus a separate fee, compounded) |
| Coverage | Coverage not published | 34 states |
| Brand-name access | Yes | Compounded only |
| Oral / sublingual | Yes | Injection only |
Graded #311 · C
Strengths
- Four-pharmacy network: Belmar, Strive, Epiq Scripts, and Casa Pharma RX
- Named prescribers on the public site: Dr. Carr (MD), Dr. Tenbrink (MD), Dr. Italia (MD), Dr. Mansour (DO)
- Oral disintegrating tablet (ODT) form for both semaglutide and tirzepatide — good for needle-averse patients
- Pricing, drug list, pharmacy partners, and physician roster all visible on the public site
- LegitScript Certified
Where it loses points
- Promo pricing ($179 semaglutide injection) is prominent, but post-promo maintenance pricing isn't shown
- No titration-ladder pricing — you can't see costs at 1.0 mg or 2.4 mg maintenance
- Refund / cancellation policy not stated on the homepage
- Lab-work requirement not stated
- Operating corporate entity not disclosed
Graded #496 · C
Strengths
- Serves 34 states — meaningful nationwide footprint
- Asynchronous model removes friction for patients who don't want a video visit
- Independent licensed prescribers retain full clinical authority
Where it loses points
- Active Novo Nordisk false-advertising lawsuit alleging trademark infringement and marketing compounded drugs as FDA-approved alternatives
- Active DOJ/FTC enforcement alleging undisclosed subscription terms, locked cancellation, and unauthorized health-data sharing
- Founder previously ran Cerebral, which settled with the FTC in 2024 over similar deceptive practices
- Recently rebranded to Gronk Inc. amid active enforcement
- FDA issued this company a warning letter dated 1 September 2025; the letter is public in FDA's warning-letter database
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.